Expression and Clinical Significance of Long-chain Noncoding RNA LINC00261 in Colon Cancer

Zhou, Zailong; Ma, Jiamin

doi:10.7754/clin.lab.2019.190402

Cited by 8 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, increasing evidence has discovered that lncRNAs play crucial roles in COAD progression, and some lncRNAs were regarded as underlying diagnostic and therapeutic targets for COAD (Liao et al, 2020; Zhou & Ma, 2019). In this study, we found a novel lncRNA BVES‐AS1 which was expressed at a low level in COAD cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

BVES‐AS1 inhibits the malignant behaviors of colon adenocarcinoma cells via regulating BVES

Wen

Wang

Xie³

et al. 2021

Cell Biology International

View full text Add to dashboard Cite

The underexpression of the long noncoding RNA blood vessel epicardial substance antisense RNA 1 (BVES‐AS1) has been shown in colon adenocarcinoma (COAD) patients. However, its role in COAD remains to be explored. This study aimed to investigate the function and potential mechanism of BVES‐AS1 in COAD. Colony formation, Cell Counting Kit‐8, JC‐1 mitochondrial membrane potential assay, wound healing, transwell, and western blot analyses were used to measure cell proliferation, apoptosis, migration, invasion, and epithelial‐mesenchymal transition (EMT) in COAD cells. RNA pull‐down, luciferase reporter, and RNA binding protein immunoprecipitation assays were used to detect the interaction of BVES‐AS1 and downstream genes. BVES‐AS1 was expressed at low levels in COAD cells. Overexpressed BVES‐AS1 inhibited COAD cell proliferation, migration, invasion, and EMT while elevating cell apoptosis. Mechanistically, BVES‐AS1 functioned as a competing endogenous RNA sponging miR‐522‐3p to regulate the expression of nearby gene blood vessel epicardial substance (BVES). Besides this, BVES‐AS1 recruited TATA‐box binding protein associated factor 15 (TAF15) to promote BVES messenger RNA stability. Taken together, our study confirmed that BVES‐AS1 inhibited COAD progression via interacting with miR‐522‐3p and TAF15 to regulate BVES expression, which might offer a perspective for COAD treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Recently, lncRNAs have been proven to be closely linked to the progression of COAD (Xing et al, 2018). LINC00261 is a new biomarker for assessing the recurrence‐free survival of COAD (Zhou & Ma, 2019). LINC00491 facilitates cell proliferation and invasion of COAD (Wan et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

BVES‐AS1 inhibits the malignant behaviors of colon adenocarcinoma cells via regulating BVES

Wen

Wang

Xie³

et al. 2021

Cell Biology International

View full text Add to dashboard Cite

show abstract

“…Hence, we suggest that fucoidan play an anti-tumor effect by regulating the expression level of lncRNAs. In our study, we select a lncRNA named LINC00261, which was proved in other studies to play an anti-tumor role by regulating the expression of downstream microRNA (59,69,70). We proved that LINC00261 could inhibit the tumor characteristics of MHCC-97H cells by regulating miR-522-3p in HCC.…”

Section: Discussionmentioning

confidence: 82%

Fucoidan Inhibits the Progression of Hepatocellular Carcinoma via Causing lncRNA LINC00261 Overexpression

Wei

Chen

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) as a main type of primary liver cancers has become one of the most deadly tumors because of its high morbidity and poor prognosis. Fucoidan is a family of natural, heparin-like sulfated polysaccharides extracted from brown algae. It is not only a widely used dietary supplement, but also participates in many biological activities, such as anti-oxidation, anti-inflammation and anti-tumor. However, the mechanism of fucoidan induced inhibition of HCC is elusive. In our study, we demonstrated that fucoidan contributes to inhibiting cell proliferation in vivo and in vitro, restraining cell motility and invasion and inducing cell cycle arrest and apoptosis. According to High-Throughput sequencing of long-non-coding RNA (lncRNA) in MHCC-97H cells treated with 0.5 mg/mL fucoidan, we found that 56 and 49 lncRNAs were correspondingly up- and down-regulated. LINC00261, which was related to the progression of tumor, was highly expressed in fucoidan treated MHCC-97H cells. Moreover, knocking down LINC00261 promoted cell proliferation by promoting the expression level of miR-522-3p, which further decreased the expression level of downstream SFRP2. Taken together, our results verified that fucoidan effectively inhibits the progression of HCC via causing lncRNA LINC00261 overexpression.

show abstract

“…Moreover, the up-regulation of LINC00261 was found to suppress cell-colony formation and to accelerate apoptosis [ 66 ]. Clinically, the low expression of LINC00261 was reported to be an independent risk factor for CRC patients that influenced recurrence-free survival time after surgery operation [ 67 ]. These findings suggest that LINC00261 may also be a potential therapeutic target for CRC.…”

Section: Introductionmentioning

confidence: 99%

LINC00261: a burgeoning long noncoding RNA related to cancer

Zhang

Gao

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs), are transcripts longer than 200 nucleotides that are considered to be vital regulators of many cellular processes, particularly in tumorigenesis and cancer progression. long intergenic non-protein coding RNA 261 (LINC00261), a recently discovered lncRNA, is abnormally expressed in a variety of human malignancies, including pancreatic cancer, gastric cancer, colorectal cancer, lung cancer, hepatocellular carcinoma, breast cancer, laryngeal carcinoma, endometrial carcinoma, esophageal cancer, prostate cancer, choriocarcinoma, and cholangiocarcinoma. LINC00261 mainly functions as a tumor suppressor that regulates a variety of biological processes in the above-mentioned cancers, such as cell proliferation, apoptosis, motility, chemoresistance, and tumorigenesis. In addition, the up-regulation of LINC00261 is closely correlated with both favorable prognoses and many clinical characteristics. In the present review, we summarize recent research documenting the expression and biological mechanisms of LINC00261 in tumor development. These findings suggest that LINC00261, as a tumor suppressor, has bright prospects both as a biomarker and a therapeutic target.

show abstract

Expression and Clinical Significance of Long-chain Noncoding RNA LINC00261 in Colon Cancer

Cited by 8 publications

References 0 publications

BVES‐AS1 inhibits the malignant behaviors of colon adenocarcinoma cells via regulating BVES

BVES‐AS1 inhibits the malignant behaviors of colon adenocarcinoma cells via regulating BVES

Fucoidan Inhibits the Progression of Hepatocellular Carcinoma via Causing lncRNA LINC00261 Overexpression

LINC00261: a burgeoning long noncoding RNA related to cancer

Contact Info

Product

Resources

About